FDA Approves Sevabertinib as First-Line Treatment for HER2-Mutant Lung Cancer

The U.S. Food and Drug Administration (FDA) has approved Bayer's Sevabertinib as a first-line treatment for adults with HER2-mutant lung cancer. Data published in the New England Journal of Medicine confirm the drug's high potency against complex exon 20 insertion mutations. Sevabertinib also provides a complementary mechanism by blocking specific epidermal growth factor receptor mutants while minimizing activity against normal wild-type receptors.